-
-
-
-
-
-
-
Agios submits application for accelerated approval of mitapivat in sickle cell
-
-
-
-
-
-
-
Stifel: 'we think FULC as a soon-to-be ph3 SCD company is significantly under-appreciated'
-
-
-
-
-
-
-
Agios Pharma (AGIO) removed from Upside 30-Day Catalyst Watch at Citi
-
-
-
-
-
-
-
Citi Starts Agios Pharma (AGIO) at Buy, PT $38
-
-
-
-
-
-
-
RBC Capital Downgrades Agios Pharma (AGIO) to Sector Perform
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)
-
-
-
-
-
-
-
Agios' PYRUKYND approved for thalassemia treatment in Saudi Arabia
-
445,877 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

